ic acid (4), then through oximation, reduction and (Boc)2O protection to give the N -Boc-3′-hydroxyadamantylglycine(6), then was treated with quinidine to get (S)- N -Boc-3′-hydroxyadamantylglycine(I) and quinine to get (R)– N -Boc-3′-hydroxyadamantylglycine(II). Finally, Compound II was racemized by dicyclohexylcarbodiimide (DCC) and sodium hydride (NaH) to afford compound 6. In this route, the overall
(S) -N -Boc-3'-羟基
金刚烷基甘
氨酸 (I)是
沙格列汀用于2型糖尿病(T2
DM)的重要中间体。由1-
金刚烷羧酸(1)与
硫酸/
硝酸,VHA试剂(SOCl 2 /
DMF)和
丙二酸二乙酯钠温和反应制得,然后进行
水解,脱羧,碱化和氧化处理,得到2-( 3-羟基-1-
金刚烷基)-2-氧
乙酸(4),然后通过
肟化,还原和(Boc)2 O保护得到 N - Boc -3'-羟基
金刚烷基甘
氨酸 (6),然后用
奎尼丁处理得到(S) -N -Boc-3′-羟基
金刚烷基甘
氨酸 (I)和
奎宁得到(R)– N -Boc-3'-羟基
金刚烷基甘
氨酸(II)。最后,用二环己基碳二
亚胺(
DCC)和氢化
钠(NaH)使化合物II消旋,得到化合物6。在这种方法中,制备化合物I的总产率为约35%,对映体过量(ee)达到99%。该途径为制备(S) -N -Boc-3'-羟基
金刚烷基甘
氨酸 提供了新思路 。